<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li S</submitter><funding>NICHD NIH HHS</funding><pagination>47</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10329655</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>Knowledge gaps that limit the development of therapies for polycystic ovary syndrome (PCOS) concern various environmental factors that impact clinical characteristics. Circadian dysrhythmia contributes to glycometabolic and reproductive hallmarks of PCOS. Here, we illustrated the amelioration of Limosilactobacillus reuteri (L. reuteri) on biorhythm disorder-ignited dyslipidemia of PCOS via a microbiota-metabolite-liver axis. A rat model of long-term (8 weeks) darkness treatment was used to mimic circadian dysrhythmia-induced PCOS. Hepatic transcriptomics certified by in vitro experiments demonstrated that increased hepatic galanin receptor 1 (GALR1) due to darkness exposure functioned as a critical upstream factor in the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway to suppress</pubmed_abstract><journal>NPJ biofilms and microbiomes</journal><pubmed_title>Alleviation of Limosilactobacillus reuteri in polycystic ovary syndrome protects against circadian dysrhythmia-induced dyslipidemia via capric acid and GALR1 signaling.</pubmed_title><pmcid>PMC10329655</pmcid><funding_grant_id>R21 HD085527</funding_grant_id><pubmed_authors>Jiao L</pubmed_authors><pubmed_authors>Chan WY</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Lu G</pubmed_authors><pubmed_authors>Geng X</pubmed_authors><pubmed_authors>Chu W</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Chen ZJ</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Zhai J</pubmed_authors><pubmed_authors>Sun Y</pubmed_authors><pubmed_authors>Sun K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Alleviation of Limosilactobacillus reuteri in polycystic ovary syndrome protects against circadian dysrhythmia-induced dyslipidemia via capric acid and GALR1 signaling.</name><description>Knowledge gaps that limit the development of therapies for polycystic ovary syndrome (PCOS) concern various environmental factors that impact clinical characteristics. Circadian dysrhythmia contributes to glycometabolic and reproductive hallmarks of PCOS. Here, we illustrated the amelioration of Limosilactobacillus reuteri (L. reuteri) on biorhythm disorder-ignited dyslipidemia of PCOS via a microbiota-metabolite-liver axis. A rat model of long-term (8 weeks) darkness treatment was used to mimic circadian dysrhythmia-induced PCOS. Hepatic transcriptomics certified by in vitro experiments demonstrated that increased hepatic galanin receptor 1 (GALR1) due to darkness exposure functioned as a critical upstream factor in the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway to suppress</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2025-07-04T03:05:54.733Z</modification><creation>2025-04-20T03:43:34.267Z</creation></dates><accession>S-EPMC10329655</accession><cross_references><pubmed>37422471</pubmed><doi>10.1038/s41522-023-00415-2</doi></cross_references></HashMap>